Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Assets Average (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Assets Average readings, the most recent being $794.5 million for Q1 2026.

  • On a quarterly basis, Assets Average rose 34.67% to $794.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $794.5 million, a 34.67% increase, with the full-year FY2025 number at $672.1 million, up 21.44% from a year prior.
  • Assets Average hit $794.5 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $738.0 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $794.5 million in Q1 2026 to a low of $220.8 million in Q2 2022.
  • Median Assets Average over the past 5 years was $523.0 million (2024), compared with a mean of $515.4 million.
  • Biggest five-year swings in Assets Average: fell 29.8% in 2022 and later soared 109.99% in 2023.
  • Kiniksa Pharmaceuticals International's Assets Average stood at $459.8 million in 2022, then rose by 9.76% to $504.7 million in 2023, then rose by 12.53% to $567.9 million in 2024, then grew by 29.94% to $738.0 million in 2025, then grew by 7.65% to $794.5 million in 2026.
  • The last three reported values for Assets Average were $794.5 million (Q1 2026), $738.0 million (Q4 2025), and $686.7 million (Q3 2025) per Business Quant data.